TrialPath
← Back to searchRecruiting

Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment

NCT01205815 · Vanderbilt-Ingram Cancer Center
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
The purpose of this research is to identify biological characteristics occurring in the initiation and progression of melanoma.
Eligibility criteria
Inclusion criteria * Pathologically-proven diagnosis of melanoma. * Patient must have a test or procedure that has the potential to provide left-over tissue that can be banked for future research purposes OR the patient has already had a diagnostic or therapeutic procedure but who has not yet been approached to participate is also eligible. Exclusion criteria * Any patient with significant contraindications to venipuncture (e.g., severe anemia) will be excluded from blood collection procedures. However, if the patient provides consent and a paraffin-embedded block or 10-15 unstained slides of their tissue diagnosis, they will not be excluded from this protocol. * Any patient unable or unwilling to provide consent.
Study design
Enrollment target: 3000 participants
Age groups: adult, older_adult
Timeline
Starts: 2010-06-03
Estimated completion: 2027-06
Last updated: 2025-09-19
Interventions
Other: Tissue and blood collection
Primary outcomes
  • Molecular changes in patients' melanoma tissue (at 120 months)
Sponsor
Vanderbilt-Ingram Cancer Center · other
Contacts & investigators
ContactVanderbilt-Ingram Service for Timely Access · contact · 800-811-8480
InvestigatorDouglas Johnson, M.D. · principal_investigator, Vanderbilt-Ingram Cancer Center
All locations (1)
Vanderbitl-Ingram Cancer CenterRecruiting
Nashville, Tennessee, United States